- Open Access
A general method to eliminate laboratory induced recombinants during massive, parallel sequencing of cDNA library
© Waugh et al.; licensee BioMed Central. 2015
- Received: 3 December 2014
- Accepted: 16 March 2015
- Published: 9 April 2015
Massive, parallel sequencing is a potent tool for dissecting the regulation of biological processes by revealing the dynamics of the cellular RNA profile under different conditions. Similarly, massive, parallel sequencing can be used to reveal the complexity of viral quasispecies that are often found in the RNA virus infected host. However, the production of cDNA libraries for next-generation sequencing (NGS) necessitates the reverse transcription of RNA into cDNA and the amplification of the cDNA template using PCR, which may introduce artefact in the form of phantom nucleic acids species that can bias the composition and interpretation of original RNA profiles.
Using HIV as a model we have characterised the major sources of error during the conversion of viral RNA to cDNA, namely excess RNA template and the RNaseH activity of the polymerase enzyme, reverse transcriptase. In addition we have analysed the effect of PCR cycle on detection of recombinants and assessed the contribution of transfection of highly similar plasmid DNA to the formation of recombinant species during the production of our control viruses.
We have identified RNA template concentrations, RNaseH activity of reverse transcriptase, and PCR conditions as key parameters that must be carefully optimised to minimise chimeric artefacts.
Using our optimised RT-PCR conditions, in combination with our modified PCR amplification procedure, we have developed a reliable technique for accurate determination of RNA species using NGS technology.
- Recombination rate
- Mutation rate
The massive capacity of next generation sequencing (NGS) technologies is revolutionising transcriptome analysis and can be used to assess the complexity of viral diversity in highly mutable, genomes of RNA viruses that cause disease in humans, such as human immunodeficiency virus-1 (HIV-1). Accurate detection of clinically relevant, drug-resistant mutations is important for adapting patient drug regimes. In addition, deep sequencing is used to investigate host cell and viral factors that impact on the genetic diversity of HIV-1.
The production of cDNA libraries for NGS involves laboratory procedures that include RNA extraction, reverse transcription PCR (RT-PCR) to generate cDNA followed by PCR amplification. Importantly, the amplification of each cDNA species must remain clonal, especially when studying the diversity of RNA species. The laboratory manipulations necessary for library generation are recognised as potential sources of artefactual recombination. Several papers have addressed the issue of minimising PCR artefacts [1-3] and there is growing interest in optimising RT-PCR techniques to enable accurate analysis of patient RNA virus load and early detection of the emergence of drug resistant quasi-species [3-6].
Thus, in both the clinical and experimental setting there is a recognised need to identify sources of laboratory induced error and to minimise these to obtain a robust technique for generating DNA libraries for NGS that faithfully reflect the underlying genetic diversity of the virus. In the current study there were three aspects of sample processing that we were particularly interested in assessing and optimising: RNA concentration during first strand synthesis; effect of RNase H activity and PCR cycling conditions. To assess the impact of these on the introduction of recombinant artefact we used a mix of authentic wild-type (WT) HIV-1 and marker virus containing silent mutations that are ideal for assessing sources of laboratory induced recombination events during cDNA library preparation. The marker virus is biologically and functionally indistinguishable from the parental WT virus, and thus mimics the closely related, yet genetically distinct, quasi-species that exist in infected patients.
Using our viral system we have produced populations of genetically distinct, but functionally identical, homozygous HIV-1 particles (containing either WT or marker RNA) and also heterozygous HIV-1 (containing a strand of WT and marker RNA) as sources of viral RNA species for analysis of laboratory sources of recombination. We have characterised the important sources of error in RT-PCR that contribute to artificial chimera formation and, in combination with our modified PCR amplification procedure  and analytic tools , have developed a reliable technique for accurate determination of viral diversity using NGS. Our key observations are that (i) the amount of RNA used in the reverse transcription PCR must be kept to a minimum; (ii) approximately 2,500 copies of cDNA should be input into the PCR amplification step and (iii) PCR cycles should be optimised so that the amplification reaction is stopped whilst still in the linear phase (27–29 cycles). Furthermore, we have also shown that homologous recombination during transfection, sometimes perceived as a source of experimental bias during virus production [8-11], is a negligible source of error and the effect of laboratory manipulations on estimates of mutation rate can be readily managed with appropriate rigorous experimental procedure.
Increasing RNA concentration correlates with artificial chimera formation in reverse transcription PCR (RT-PCR)
Recombination and mutation rates
a. Recombination rates
Lower 95% CI bound
Upper 95% CI bound
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
b. Mutation Rates
Lower 95% CI bound
Upper 95% CI bound
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
wt + mk mix
Effect of PCR cycling conditions on chimera formation
RNAse H activity has minor impact on chimera formation
The HIV-1 genome is comprised of 2 identical (or near identical) strands of RNA, that are used as template during reverse transcription to produce a cDNA molecule for integration into the host genome during infection. Template switching during reverse transcription is acknowledged as an efficient mediator of viral diversity, generating recombinant HIV RNA species that are a mixture of the two parental RNA strands. Template switching is thought to be facilitated through the action of the RNase H activity of the HIV-1 RT whereby a dynamic balance exists between the polymerase activity of RT and the endonuclease activity of RNase H that cleaves the RNA from the nascent cDNA polymer [12,13]. According to the copy-choice model, RNase H degrades the RNA template from the RNA/cDNA hybrid thus permitting the newly synthesised DNA to base-pair with the similar sequence on the other RNA strand.
Transfection of HEK293T cells does not contribute significantly to chimera formation
Several groups have developed experimental protocols to measure recombination rates of HIV-1 and other viruses that require the production of virus from producer cell lines using standard transfection methods and then use of the virus to infect cell lines and primary cells [14-17]. Thus, transfection presents another potential source of artificial recombination. Indeed, previous studies have shown that mammalian cells possess the enzymatic machinery to effect homologous recombination and that (i) DNA topology affects homologous recombination with linear molecules the preferred substrates , (ii) homologous recombination can occur between single stranded and double stranded DNA  and (iii) nicked DNA significantly enhances the frequency of homologous recombination in transfected cells [8,11]. Our system of marker and wild type plasmids provides a unique opportunity to assess the role of homologous recombination as a source of chimeric artefact during transfection. HEK293T cells were transfected with proviral DNA plasmids to produce control viruses. We extracted RNA from either an equal mixture of homozygous WT and homozygous MK viruses (Figure 1 top) or from heterozygous WT/MK virus (based on p24 values) (Figure 1 bottom). Our sequencing data reveals that the heterozygous virus is composed of ~50% WT: 50%MK HIV-1 sequences (data not shown). This is consistent with the premise that the plasmids used in transfection were equally transcribed. Given that: (i) the WT and MK plasmids were transfected in equal ratios, (ii) each virion contains two copies of RNA and (iii) the heterozygous virus also has equal ratios of WT and MK virus, then the simplest and most likely scenario is that 25% of virions contain two copies of WT virus, 25% of virions contain two copies of MK virus and 50% of virions contain one copy of WT virus and one copy of MK virus. Any other scenario is less likely and would require special pleading, and therefore we believe that our Mendelian assumption is valid. This is also consistent with data published by Chen et al.  who were able to directly discriminate between two different RNA molecules encapsidated within the same virion particle and confirmed that, using standard transfection techniques, RNA co-packaging was an efficient process (more than 90% of virions contained RNA) and that ~48% of virions that contained RNA were heterozygous, as predicted by the Hardy-Weinberg model.
Samples were prepared using optimised RT-PCR (160 ng input RNA template) and resulting cDNA was diluted so that approximately 2,500 copies of HIV-1 cDNA were used as template and amplified using our optimised PCR protocols. The mixture of homozygous RNA species provides a baseline measure of artefactual recombination attributable to downstream laboratory manipulations, as any recombination between these homozygous viruses could only have occurred during RT-PCR, PCR or 454 sequencing. Thus, comparison of the rate of recombination between the mix of homozygous viruses (equal mix of WT plus MK) with that of the truly heterozygous viral RNA provides a novel and accurate estimate of the rate of transfection-induced recombination.
Any analysis of viral diversity through experimentation raises the possibility that recombinant quasi-species could arise as a result of laboratory manipulations, including virus production (transfection), infection of primary cells or cell lines, RNA extraction and conversion of RNA to cDNA (RT-PCR) and cDNA amplification. Mutations in the form of insertions, deletions or substitutions could occur during any of these procedures and deep sequencing. Further, with the vast improvements in treatment for HIV-1 infection that have occurred over the last 30 years, clinicians are now able to investigate the emergence of viral quasi-species in individual patients and to tailor drug regimes to counter the emergence of deleterious, drug-resistant mutants. Experimental programs to identify viral and host cell factors that affect recombination and clinical assessments of drug-resistant mutants require sensitive and validated methods to discern ‘true’ in vivo viral species from laboratory induced artefacts.
We produced genetically distinct, authentic HIV-1 viruses to investigate the most obvious sources of laboratory induced error, namely: transfection, RT-PCR and PCR conditions. Using our system we have been able to compare recombination rates between a mix of homozygous viruses (where recombination could only be due to laboratory manipulations) and heterozygous virus (where recombination could be due to laboratory manipulations or to the transfection process). Our data show that the transfection of HEK293T cells with plasmid DNA is an insignificant source of recombination and affirms the appropriateness of using transfection-derived viruses as model systems to identify viral and host cell factors that affect recombination. We stress the importance of using high quality plasmid DNA for the production of virus to minimise the risk of homologous recombination within the culture system. This is consistent with previous studies that have shown that nicked, non-circular plasmid DNA enhances the occurrence of homologous recombination between plasmid and homologous chromosomal regions [8,10].
By comparison considerable attention must be paid to the conditions of RT-PCR and PCR to minimise the occurrence of artefactual chimeras. We postulated that increasing the concentration of RNA during first strand synthesis would decrease the proximal distance of strands of RNA and enhance strand transfer events, thus resulting in increased recombination rates. Our data confirm that RNA concentration in RT-PCR is a critical parameter. Surprisingly, even acceptable ‘mid-range’ concentrations of RNA template (1600 ng, well within the manufacturer’s suggested range) at the RT-PCR step can result in detection of false chimeras. Thus we show that even when using a high fidelity enzyme with low RNase H activity, RNA concentration is a critical factor and can have a marked effect on estimates of recombination rate. We recommend that input RNA be kept to a minimum (100-200 ng) which, in this study, is at least 10-fold lower than that recommended by the manufacturer. In accord with Di Giallonardo et al. , we have found that RNaseH activity does not contribute significantly to artificial recombination when the concentration of RNA template is low.
The PCR amplification of DNA is highly susceptible to artefact. Previous studies have shown that input copy number [1,2], annealing and extension steps  and number of PCR cycles [1,3] are critical parameters, requiring optimisation to minimise formation of artificial chimeras. In this study we used a 2-step PCR with optimised, limited input copy number (~2500 copies), shown to minimise artificial chimeras . Varying only the number of PCR cycles performed, we have shown that stopping the PCR amplification in the linear phase minimises false recombinants whereas increasing cycle number to 35 dramatically increased the detection of false chimeras. Our data show directly that while increasing the input RNA concentration and PCR cycle might generate a larger viral cDNA population for analysis, such an approach is likely to compromise the quality of sequencing data obtained. We have used the data to develop a protocol that minimises the introduction of artificial recombinants during 454 library generation. The salient features of our protocol are: (i) restricted RNA input (100-200 ng) at RT-PCR for first strand synthesis using a high fidelity RT; (ii) ~2,500 copies of cDNA used as template for subsequent PCR amplification; and (iii) restricting PCR cycles to ~27-29 cycles to ensure that the amplification process is terminated in the linear phase of amplification. These studies have direct relevance to the clinical setting where minimisation of artefact is essential to obtaining accurate measurements of viral diversity and detection of drug resistant mutations. The articulation of these critical parameters (RNA concentration, choice of enzyme, input cDNA copies and PCR cycling parameters) informs our own program of experimental research to identify viral and host cell factors that impact recombination rate and viral diversity.
Transfection and virus production
Homozygous virus was produced by transfection of HEK293T cells with either WT or MK plasmid and heterozygous virus by co-transfection of equimolar amounts of WT and MK plasmids using polyethyleneimine (PEI; Polysciences). Based on Mendelian genetics, the heterozygous virus will be composed of 3 distinct populations: 25% of virus particles will contain 2 strands of WT RNA; 25% will contain 2 strands of MK RNA and 50% will be truly heterozygous, containing a strand of WT and MK RNA. Sixteen to twenty hours after transfection cell cultures were gently washed with PBS and replenished with fresh media. At 48 hr post-transfection viral supernatants were harvested, clarified by centrifugation, layered over a 20% sucrose cushion and centrifuged for 1 hour at 25,500 g, 4oC. Concentrated virus was then further refined by layering onto a sucrose gradient (consisting of 9 sucrose layers ranging from 50% sucrose to 32% sucrose in 2.5% decrements) and centrifuged for 16 h, 25,500 g, 4°C to reduce plasmid contamination. Concentrated virus was resuspended in RPMI (Invitrogen), aliquoted and stored at −80°C. Quantitation of virus was done with an ELISA assay to detect viral capsid protein using the HIV-1 p24CA Antigen Capture Assay (Frederick National Laboratory-AIDS and Cancer virus program).
RNA isolation and cDNA synthesis
Viral RNA was isolated using TRI-reagent (Qiagen) according to the manufacturer’s recommendations. RNA was reverse transcribed using gene-specific primer, gag4(4195)Rv (5′ ACATTTCCAACAGCCCTTTTTCCTAG 3′), and either SuperScript III reverse transcriptase (RT) (Invitrogen) engineered to have minimal RNaseH activity or AMV RT (with RNAse H activity) (Promega). Variable amounts of input RNA template were used in optimal and ‘stress’ conditions, as described in the results section. To gauge plasmid DNA contamination, RNA samples were processed without reverse transcriptase (RT) and then analysed by qPCR using primers for gag1 amplicon. In all cases there was a minimum 10 cycle threshold differences between samples processed with the RT and those without, indicating very low levels of plasmid contamination.
Primers used for amplicon generation
a. Barcode sequences
b. HIV-1 sequences common to WT and MK transcripts
Amplicon length (nt)
5′ GAGATGGGTGCGAGAGCGTC 3′
5′ TGTGTCAGCTGCTGCTTGCTG 3′
5′ ACCAAGGAAGCCTTAGATAAGATAGAGGAAGAG 3′
5′ TGAAGGGTACTAGTAGTTCCTGCTATGTCACTTC 3′
5′ GATAGATTGCATCCAGTGCATGCAG 3′
5′ GCTTTTAAAATAGTCTTACAATCTGGGTTCGC 3′
5′ TCTGGACATAAGACAAGGACCAAAGG 3′
5′ ACATTTCCAACAGCCCTTTTTCCTAG 3′
PCR amplification conditions
Modified PCR cycling conditions were used as described previously  to reduce chimera formation during PCR amplification. Briefly, the PCR mix (total volume, 15ul) consisted of limiting DNA template (approximately 2,500 copies in 5 ul), 1x HF buffer (Thermo Scientific), 200uM dNTP (NEB), 400nM of each barcoded primer and 0.3U of Phusion DNA polymerase (Thermo Scientific). Five to ten replicates were performed to produce sufficient DNA product for library generation and sequencing. Additionally, to enable monitoring of the reaction using qPCR, duplicates were included containing 0.5x SYBR Green 1 (Life Technologies). PCR cycling conditions were 98°C for 30s, followed by a variable number of cycles of 98°C for 10s and 72°C for 1 min. PCR cycles were selected either to minimise PCR-induced chimera formation (25–29 cycles) or to maximise DNA product and to ‘stress’ PCR conditions (35-40cycles).
Library generation and 454 sequencing
PCR replicates were pooled and purified using the Wizard SV gel and PCR Clean-Up System (Promega) following the recommended protocol and quantitated against a plasmid standard curve, generated with gag1 amplicon, ranging from 102-106 copies of DNA per microlitre. Aliquots of each amplicon (gag1-gag4) for each sample were pooled to construct sequencing libraries using the 454 library preparation kit (Roche). Emulsion PCR and sequencing were performed using standard XLR70 chemistry at the Institute for Immunology and Infectious Diseases, Perth, Australia.
Sequencing analysis was performed using software custom written in BioRuby. Chimera formation, expressed as recombination rate per 1000 nucleotides (REPN), and statistical comparisons performed as previously described . Recombination is detected by monitoring the linking of marker points in the HIV-1 gag gene from WT and MK genomes into a single chimeric genome.
- Smyth RP, Schlub TE, Grimm A, Venturi V, Chopra A, Mallal S, et al. Reducing chimera formation during PCR amplification to ensure accurate genotyping. Gene. 2010;469(1–2):45–51.View ArticlePubMedGoogle Scholar
- Di Giallonardo F, Zagordi O, Duport Y, Leemann C, Joos B, Kunzli-Gontarczyk M, et al. Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination. PLoS One. 2013;8(9):e74249.View ArticlePubMed CentralPubMedGoogle Scholar
- Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, et al. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology. 2013;10:18.View ArticlePubMed CentralPubMedGoogle Scholar
- Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, et al. Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One. 2012;7(5):e36494.View ArticlePubMed CentralPubMedGoogle Scholar
- Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol. 2012;86(11):6231–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, Zeldis I, et al. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J Clin Microbiol. 2013;51(3):880–6.View ArticlePubMed CentralPubMedGoogle Scholar
- Schlub TE, Smyth RP, Grimm AJ, Mak J, Davenport MP. Accurately measuring recombination between closely related HIV-1 genomes. PLoS Comput Biol. 2010;6(4):e1000766.View ArticlePubMed CentralPubMedGoogle Scholar
- Kucherlapati RS, Eves EM, Song KY, Morse BS, Smithies O. Homologous recombination between plasmids in mammalian cells can be enhanced by treatment of input DNA. Proc Natl Acad Sci U S A. 1984;81(10):3153–7.View ArticlePubMed CentralPubMedGoogle Scholar
- Wake CT, Vernaleone F, Wilson JH. Topological requirements for homologous recombination among DNA molecules transfected into mammalian cells. Mol Cell Biol. 1985;5(8):2080–9.PubMed CentralPubMedGoogle Scholar
- Rauth S, Song KY, Ayares D, Wallace L, Moore PD, Kucherlapati R. Transfection and homologous recombination involving single-stranded DNA substrates in mammalian cells and nuclear extracts. Proc Natl Acad Sci U S A. 1986;83(15):5587–91.View ArticlePubMed CentralPubMedGoogle Scholar
- Sprengel R, Varmus HE, Ganem D. Homologous recombination between hepadnaviral genomes following in vivo DNA transfection: implications for studies of viral infectivity. Virology. 1987;159(2):454–6.View ArticlePubMedGoogle Scholar
- Coffin JM. Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. J Gen Virol. 1979;42(1):1–26.View ArticlePubMedGoogle Scholar
- Hwang CK, Svarovskaia ES, Pathak VK. Dynamic copy choice: steady state between murine leukemia virus polymerase and polymerase-dependent RNase H activity determines frequency of in vivo template switching. Proc Natl Acad Sci U S A. 2001;98(21):12209–14.View ArticlePubMed CentralPubMedGoogle Scholar
- Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A. 2004;101(12):4204–9.View ArticlePubMed CentralPubMedGoogle Scholar
- Dapp MJ, Clouser CL, Patterson S, Mansky LM. 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1. J Virol. 2009;83(22):11950–8.View ArticlePubMed CentralPubMedGoogle Scholar
- Dapp MJ, Heineman RH, Mansky LM. Interrelationship between HIV-1 fitness and mutation rate. J Mol Biol. 2013;425(1):41–53.View ArticlePubMed CentralPubMedGoogle Scholar
- Nguyen LA, Kim DH, Daly MB, Allan KC, Kim B. Host SAMHD1 protein promotes HIV-1 recombination in macrophages. J Biol Chem. 2014;289(5):2489–96.View ArticlePubMed CentralPubMedGoogle Scholar
- Chen J, Nikolaitchik O, Singh J, Wright A, Bencsics CE, Coffin JM, et al. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proc Natl Acad Sci U S A. 2009;106(32):13535–40.View ArticlePubMed CentralPubMedGoogle Scholar
- Englund G, Theodore TS, Freed EO, Engelman A, Martin MA. Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol. 1995;69(5):3216–9.PubMed CentralPubMedGoogle Scholar
- Schlub TE, Grimm AJ, Smyth RP, Cromer D, Chopra A, Mallal S, et al. Fifteen to twenty percent of HIV substitution mutations are associated with recombination. J Virol. 2014;88(7):3837–49.View ArticlePubMed CentralPubMedGoogle Scholar
- Smyth RP, Schlub TE, Grimm AJ, Waugh C, Ellenberg P, Chopra A, et al. Identifying recombination hot spots in the HIV-1 genome. J Virol. 2014;88(5):2891–902.View ArticlePubMed CentralPubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.